Conclusions

Nintedanib had the same benefit in reducing the progression of IPF in patients with ≥5 and <5 comorbidities at baseline.
Discontinuation of nintedanib due to adverse events was more common in patients with ≥5 than <5 comorbidities at baseline.
The identification and treatment of comorbidities are important aspects of the management of patients with IPF.